Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 56.1% | 57.3% | 55.9% | 57.3% | 59.6% | 56.5% |
| All xnmsc 0-24 | 27.7% | 37.4% | 25.2% | 47.5% | 47.2% | 29.7% |
| All xnmsc 25-59 | 65.5% | 67.8% | 64.8% | 69.8% | 69.4% | 67.2% |
| All xnmsc 60-79 | 60.8% | 61.5% | 60.7% | 61.3% | 63.0% | 61.2% |
| All xnmsc 80+ | 37.1% | 37.0% | 37.3% | 34.5% | 40.0% | 36.3% |
| All registrations | 43.8% | 45.3% | 43.3% | 47.3% | 45.5% | 45.1% |
| Haematology | 18.0% | 36.8% | 13.9% | 47.2% | 72.8% | 13.3% |
| Head and Neck | 74.2% | 77.9% | 73.4% | 74.6% | 81.4% | 82.1% |
| Lower GI | 75.8% | 74.8% | 76.0% | 75.4% | 72.9% | 75.0% |
| Upper GI | 72.4% | 73.1% | 72.4% | 71.2% | 76.1% | 72.5% |
| HPB | 27.4% | 23.9% | 28.5% | 20.2% | 24.5% | 22.3% |
| Trachea, Bronchus & Lung | 21.8% | 21.7% | 21.5% | 23.3% | 16.2% | 25.7% |
| Melanoma of skin | 0.4% | 0.3% | 0.4% | 0.7% | 0.0% | 0.1% |
| Breast | 95.5% | 95.7% | 95.4% | 96.2% | 95.8% | 95.2% |
| Cervix | 82.6% | 78.3% | 83.2% | 82.3% | 63.0% | 84.6% |
| Other Female Genitals | 76.0% | 76.4% | 76.1% | 72.4% | 78.4% | 78.8% |
| Prostate | 78.2% | 78.2% | 78.1% | 78.8% | 75.7% | 80.1% |
| Kidney | 53.4% | 53.7% | 53.4% | 52.4% | 55.1% | 53.8% |
| Bladder | 79.6% | 81.9% | 79.3% | 78.0% | 87.2% | 82.9% |
| Brain and CNS | 65.4% | 58.0% | 67.1% | 63.0% | 55.7% | 46.3% |
| Thyroid and other endocrine glands | 18.2% | 16.5% | 18.2% | 28.5% | 3.8% | 15.5% |
| CUP | 19.6% | 17.6% | 19.9% | 19.3% | 12.2% | 19.1% |
| Other invasive cancer | 29.6% | 29.1% | 30.0% | 26.9% | 31.9% | 27.5% |